Cat. No. 3314
Chemical Name: 4-(2,3-Dihydro-1,4-benzodioxin-6-yl
Biological ActivityCompetitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Flight (2008) Getting rid of JNK. Nat.Rev.Drug Disc. 7 975.
Haas and Writer (2008) Block JNK at the dock. SCiBX 1 1.
Stebbins et al (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc.Natl.Acad.Sci.USA 105 16809.
If you know of a relevant citation for this product please let us know.
Keywords: BI 78D3, supplier, Selective, competitive, JNK, inhibitors, MAPK, Signaling, Signalling, c-Jun, N-Terminal, Kinases, SAPKs, Stress-Activated, Protein, Mitogen-Activated, p38, BI78D3
Find multiple products by catalog number
New Products in this Area
Potent and selective p38α inhibitorDBM 1285 dihydrochloride
p38 MAPK inhibitor; anti-inflammatorySR 3576
Highly potent and selective JNK3 inhibitorCEP 1347
Inhibitor of JNK signaling
August 30 - September 4, 2014
Booth Number: 22